Radius Health (RDUS) Stock Forecast, Price & News

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Radius Health.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.19. During the same period in the previous year, the firm posted ($0.34) earnings per share.
View Radius Health's earnings history.

What price target have analysts set for RDUS?

5 brokerages have issued 1-year price targets for Radius Health's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate Radius Health's stock price to reach $9.60 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:

• Mr. G. Kelly Martin, CEO, Pres & Director (Age 63, Pay $612.37k)
• Mr. Salvador Grausso III, Sr. VP & Head of U.S. Patient access (Age 47, Pay $530.42k)
• Dr. Stavros C. Manolagas, Founder & Member of the Scientific Advisory Board
• Dr. John Thomas Potts Jr., DSc, M.D., Founder & Member of the Scientific Advisory Board (Age 90)
• Dr. Michael Rosenblatt M.D., Founder, Board Observer & Member of Scientific Advisory Board (Age 74)
• Dr. John A. Katzenellenbogen, Founder & Member of the Scientific Advisory Board
• Mr. Mark Conley, VP, CFO, Principal Accounting Officer & Treasurer (Age 60)
• Mr. Peter A. Schwartzman, Head of Corp. Fin.
• Ethan Holdaway, Head of Investor Relations
• Ms. Kim Clarke, Gen. Counsel

Who are some of Radius Health's key competitors?

Some companies that are related to Radius Health include Zentalis Pharmaceuticals (ZNTL), MannKind (MNKD), Prometheus Biosciences (RXDX), NGM Biopharmaceuticals (NGM), Agios Pharmaceuticals (AGIO), Arcutis Biotherapeutics (ARQT), Reata Pharmaceuticals (RETA), Innoviva (INVA), Vectura Group (VEGPF), BridgeBio Pharma (BBIO), Cassava Sciences (SAVA), Lyell Immunopharma (LYEL), Amneal Pharmaceuticals (AMRX), Amneal Pharmaceuticals (AMRX) and Myovant Sciences (MYOV).
View all of RDUS's competitors.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Bellevue Group AG (17.49%), State Street Corp (8.11%), Vanguard Group Inc. (7.65%), BlackRock Inc. (7.48%), Velan Capital Investment Management LP (2.99%) and UBS Group AG (2.83%). Company insiders that own Radius Health stock include James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends for Radius Health.

Which institutional investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wellington Management Group LLP, UBS Group AG, State Street Corp, Bank of New York Mellon Corp, Walleye Capital LLC, Walleye Capital LLC, and Simplex Trading LLC.
View insider buying and selling activity for Radius Health or view top insider-selling stocks.

Which institutional investors are buying Radius Health stock?

RDUS stock was bought by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Bellevue Group AG, Acadian Asset Management LLC, Eversept Partners LP, JPMorgan Chase & Co., Assenagon Asset Management S.A., BNP Paribas Arbitrage SA, and Pinz Capital Management LP. Company insiders that have bought Radius Health stock in the last two years include Rubric Capital Management Lp, and Target N V Biotech.
View insider buying and selling activity for Radius Health or or view top insider-buying stocks.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $6.12.

How much money does Radius Health make?

Radius Health has a market capitalization of $291.13 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70.18 million in net income (profit) each year or ($1.540010) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 293 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.